Comparative study of the pharmacokinetics, efficacy and safety of ET-26 in elderly and non-elderly subjects: the results of a phase I clinical trial
Fan Yang, Jing Sun, Pan-Pan Ye, Wen-Shuo Lv, Li-Ze Li, Bao-Zhong Zhao, John Van Den Anker, Yi Zheng, Bo-Wen Ke, Xiao-Ran Yang, Wei Zhao

TL;DR
A Phase I trial found that the new anesthetic ET-26 is safe and effective in both elderly and younger adults without needing dose changes.
Contribution
ET-26 shows comparable efficacy and safety in elderly and non-elderly subjects, eliminating the need for age-based dose adjustments.
Findings
ET-26 had higher exposure in elderly subjects (Cmax GMR 198.81%) but similar time to loss of consciousness.
Plasma protein binding was stable between age groups with no significant differences.
Drug-related adverse events were mild and self-limiting in both groups.
Abstract
To evaluate the pharmacokinetics, pharmacodynamics, and safety of the novel systemic intravenous anesthetic ET-26—an etomidate derivative designed to reduce adrenal suppression—in healthy elderly and non-elderly subjects. In this Phase I, single-center, non-randomized, open-label trial, 16 volunteers were enrolled: eight elderly (≥65 years, including ≥75 years) and eight non-elderly (18–64 years), matched for gender and body weight. Each received a standardized IV infusion of ET-26. Plasma concentrations were measured for plasma protein binding, Cmax, and AUC; time to loss of consciousness (LOC) and safety were assessed. In 16 subjects (8 elderly/8 non-elderly), ET-26 showed higher exposure in the elderly (Cmax GMR 198.81%, 90% CI 126.51–312.45) and AUC0−∞ was 23.5% higher (90% CI: 107.6%–141.9%) with comparable pharmacodynamics (median LOC time 1.933 min). Plasma protein binding…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHormonal Regulation and Hypertension · Intensive Care Unit Cognitive Disorders
